Expert drug discovery services

Our Discovery Services augment your own expertise or give you capacity when you need it. Our team of leading scientists runs bespoke drug discovery campaigns for our partners and is continually innovating to validate and utilize cutting edge technology in our discovery offerings.

DEEPIMMUNE ANTIBODY DISCOVERY

KEYWAY TCR DISCOVERY

TRANSLATIONAL MEDICINE

DeepImmune™
Antibody Discovery

Our most popular service offering, DeepImmune, combines Alloy’s proprietary in vivo, in vitro, and in silico technologies into one process for time- and cost-efficient discovery of human monoclonal and bispecific therapeutic antibodies. DeepImmune integrates all our platforms and methods to generate, retrieve, and assess natural immune responses enabling successful discovery of potent antibody drug candidates ready for development.

GENERATE

Combining Alloy’s rapidly expanding family of ATX-Gx™ humanized mouse strains with advanced immunization protocols to generate highly diverse immune responses even to the most challenging antigens. 

Generate
DeepImmune combines Alloy’s rapidly expanding family of ATX-Gx™ humanized mouse strains with advanced immunization strategies, custom antibody libraries, and machine learning-generated insights and libraries to generate highly diverse immune responses to even to the most challenging antigens.
Retrieve
Our DeepImmune process captures the full diversity of antigen specific B-cells through sophisticated single cell technologies, immune phage libraries, and proprietary hybridoma protocols—all supported by next generation sequencing and deep learning-assisted immune repertoire analysis.
RETRIEVE

Capturing full diversity of antigen specific B-cells through sophisticated single-cell technologies, immune phage libraries, and proprietary hybridoma protocols all supported by the next generation sequencing and Deep Learning-assisted immune repertoire analysis.  

Assess
The DeepImmune process uses an iterative design, test, learn feedback model to characterize and assess the biophysical and functional properties of your antibody hits to identify your top lead candidates by merging antibody-specific analytical methods with functional characterization and developability assessment, enabled by machine learning engine for sequence data mining.
ASSESS

Robust hit characterization and lead identification workflow merging antibody-specific analytical methods with functional characterization and developability assessment supported by machine learning engine for sequence data mining.


Click image to enlarge


“Every DeepImmune campaign brings partners a high-quality therapeutic antibody candidate to empower them through lead selection.”

Rachel Rennard, CTO, Antibodies and Head of Antibody Discovery Services Boston

How can we help?

We work together to discover the best therapeutic antibody candidate, every time.

DISCOVERY SERVICES FOR SOLUBLE TCR THERAPIES

Keyway™ TCR Discovery

Through an integrated service offering from target selection through to final characterized leads, Keyway empowers drug developers working against the 90% of proteins that aren’t accessible by conventional cancer immunotherapies. Led by Dr. Dongxing Zha—formerly of MD Anderson’s Moon Shots Research Program, ORBIT—the Keyway TCR team is developing protein engineering solutions for drugging HLA complexes while leveraging Alloy’s infrastructure.

TCRM DISCOVERY

TCR DISCOVERY & ENGINEERING

TCR-mimic Discovery
Our fully integrated offering combines our ATX-Gx mouse platform with our in vivo, in vitro, and in silico capabilities for TCRm antibody identification and bioanalytical characterization, engineering, and functional characterization.
TCR Discovery & Engineering
Our highly engineered display system integrates T cell sorting and sequencing; in vitro display including our proprietary mammalian cell display; machine-learning-guided affinity and specificity engineering; TCR libraries for naive discovery; and HLA display for specificity screening, target discovery and validation, and library on library panning.
EXPERT LEADERSHIP

“TCR-based therapeutics offer great promise to improve immunotherapies. Keyway democratizes access to TCR discovery capabilities.”

Dongxing Zha, PhD, CTO of TCR Discovery & Engineering and CEO of Keyway TCR Discovery

Translational Medicine

We accelerate partner programs by providing early insights into functional activity of therapeutic candidates generated from Alloy discovery programs across all modalities. Generally, we offer these services in line with DeepImmune for human antibody discovery and Keyway for therapeutic TCR discovery, but we can offer advice and services on a case-by-case basis for our license partners and ecosystem collaborators.

In vivo antibody discovery

We empower discovers of monoclonal, bispecific, and single domain antibodies with royalty-free access to our platforms.
Alloy Therapeutics humanized mouse antibody drug discovery platforms

Our first platform, the ATX-Gx™, is the world’s fastest growing transgenic mouse platform for human monoclonal antibody discovery. Partners may ship mice to their labs, work with an ATX-Gx certified service provide, or engage with our flagship antibody discovery service, DeepImmune.

ATX-Gx™

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industrys standard dummy text ever since the 1500s.

ATX-CLC

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industrys standard dummy text ever since the 1500s.

ATX-SiD

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industrys standard dummy text ever since the 1500s.

How can we help?

Learn more about licensing our platforms for use your lab or starting a campaign with DeepImmune.

Machine Learning

Deep learning optimized discovery

We’ve built a robust unique Deep Learning and sequencing engine that characterizes immune repertoire data, rapidly identifies novel binders, and optimizes candidates by scanning the breadth of sequence variants.

READ MORE

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industrys standard dummy text ever since the 1500s.

Supporting drug makers across 6 biologic modalities

We are also active in genetic medicines, peptides, cell therapy, and drug delivery technology through new Venture Studio companies, discovery services, and internal innovation projects.

antibody drug discovery
TCR drug discovery
ASO genetic medicines discovery
ANTIBODIES

TCRS

GENETIC MEDICINES
peptides drug discovery
chimeric antigen receptor drug discovery
biologics drug delivery
PEPTIDES
CELL THERAPIES
DELIVERY

Learn more about our work in these areas.

The best drug against your target, regardless of format

We are innovating across 6 modalities in our R&D facilities around the world and through our collaborations. Today partners can license platforms and access services in Antibodies and TCRs. We have active R&D activities and collaborations with amazing researchers around the world in all of our modalities. Our broad suite enables discovery of innovative new therapeutics with minimal restrictions.

antibody drug discovery
ANTIBODIES
TCR drug discovery

TCRS

ASO genetic medicines discovery
GENETIC MEDICINES
peptides drug discovery
PEPTIDES
Cell therapies
CELL THERAPIES
biologics drug delivery
DELIVERY

Stay in the loop as we expand with additional platforms and services across modalities.

Further our collaboration with 82VS

82VS, our affiliated Venture Studio, partners with target-rich biotech companies and scientific entrepreneurs to create new companies that can advance promising drug pipelines.

Accept Privacy Settings Here
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please read and Privacy Policy
Youtube
Consent to display content from Youtube
Vimeo
Consent to display content from Vimeo
Google Maps
Consent to display content from Google
Spotify
Consent to display content from Spotify
Sound Cloud
Consent to display content from Sound